Third-, Fourth-line Sorafenib Therapy May Not Boost Overall Survival

Third- and fourth-line sorafenib therapy does not significantly increase overall survival in patients with relapsed/refractory non–small cell lung cancer (NSCLC), according to a recent study published in the Journal of Thoracic Oncology.¹

Luis Paz-Ares, MD, PhD, of the Instituto de Investigaciones Biomédicas de Sevilla in Spain conducted the MISSION trial, a phase 3, multinational, double-blind, placebo-controlled study to examine patients with advanced relapsed/refractory NSCLC following 2 or 3 prior regimens who received either sorafenib or placebo.

Primary endpoint was overall survival, while secondary endpoints included progression-free survival and time-to-progression.

They found that median overall survival was similar between the 2 groups, while median progression-free survival and time-to-progression were significantly greater in the sorafenib group.

In 89 patients who were observed for EGFR mutations, overall survival was significantly higher in sorafenib compared to placebo. While progression-free survival was significantly longer with sorafenib in patients with either wild-type or mutated KRAS, overall survival was similar.

Reference

1. Paz-Ares L, Hirsh V, Zhang L, et al. MISSION Trial – A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens [published online ahead of print November 6, 2015]. J of Thoracic Oncol.